Trial Profile
Prospective, Single-Arm, Multicenter, Open-Label Study to Investigate the Efficacy and Tolerability of the Once Daily (OD) Memantine Treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Nov 2011
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Merz Pharmaceuticals GmbH
- 08 Dec 2008 Actual patient number (107) added as reported by ClinicalTrials.gov.
- 08 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2008 New trial record.